Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JPI-289 Phase 1 MAD in Healthy Volunteers
NCT02396069Phase 1Completed
- Sponsor
- Jeil Pharmaceutical Co., Ltd.
- Start
- Mar 2015
- Primary completion
- Aug 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in ischemic stroke comparing JPI-289 with Placebo (2 arms). Primary endpoints: Area Under the Curve at Steady State over Dosing Interval at 96 hours, Maximum Plasma Concentration at Steady State at 76 hours and 1 more. Started Mar 2015; status: completed.
02
Drugs
Amelparib
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT02396069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02396069.